Rockefeller Capital Management
CUE icon

Rockefeller Capital Management’s Cue Biopharma CUE Stock Holding History

Rockefeller Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38
Closed -$12K – 3896
2021
Q4 		$12K Buy
+38
New +$14.7K ﹤0.01% 2882

Other funds holding CUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's CUE Position: Q1 2022 in Review

Rockefeller Capital Management sold out of Cue Biopharma (CUE) in Q1 2022, closing a stake of 38 shares — an estimated $12K sold.

Rockefeller Capital Management first reported a position in CUE in Q4 2021 and held it in 1 quarter. The position peaked at $12K in Q4 2021. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Rockefeller Capital Management reported no remaining Cue Biopharma position as of Q1 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 38 Cue Biopharma shares in Q1 2022, an estimated $12K.
  • Rockefeller Capital Management first reported a position in Cue Biopharma in Q4 2021 and held it in 1 quarter.
  • Rockefeller Capital Management's Cue Biopharma position peaked at $12K in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Rockefeller Capital Management's 13F filing for Q1 2022, filed 13 May 2022.